• Kidney Transplant Rejection Drugs Tied to Pregnancy Risks in Study

    Early research found more miscarriages, birth defects among women who conceived while on these meds
    WEDNESDAY, Oct. 23 (HealthDay News) -- Drugs meant to reduce the risk of organ rejection may increase the risk of miscarriage and birth defects when taken by female kidney transplant patients, according to a new study.
    The drugs -- called mycophenolic acid products -- reduce the risk of organ rejection by suppressing the immune system. The study included 163 female transplant patients who discontinued mycophenolic acid products prior to conception and 114 who conceived while taking the anti-rejection drugs.
    Those who stopped taking mycophenolic acid products before they became pregnant had more live births (79 percent vs. 43 percent), fewer miscarriages (19 percent vs. 52 percent) and a lower rate of birth defects (6 percent vs. 14 percent) than those who were taking the drugs when they conceived.
    Women who stopped the anti-rejection drugs before they became pregnant did not have an increased risk of kidney problems, according to the study, which is scheduled for presentation in early November at an American Society of Nephrology meeting in Atlanta.
    Although the study found an association between the drugs and increased pregnancy and birth risks, it did not prove a cause-and-effect relationship. The data and conclusions also should be viewed as preliminary until published in a peer-reviewed journal.
    "The results of this study generate multiple questions. Continued close collaboration among specialists will help to better identify potential pregnancy risks in kidney transplant recipients, particularly as new immunosuppressive [drugs] are developed," study author Dr. Serban Constantinescu, of the Temple University School of Medicine, said in an American Society of Nephrology news release.
    "Individual physicians and transplant centers are encouraged to report all pregnancy exposures in transplant recipients to the National Transplantation Pregnancy Registry, which was designed specifically to assess the safety of pregnancy in solid organ transplant recipients," Constantinescu said.
    More information
    The National Kidney Foundation has more about pregnancy and kidney disease (http://www.kidney.org/atoz/content/pregnancy.cfm ).
    SOURCE: American Society of Nephrology, news release, Oct. 23, 2013
  • Join WellZones today.

    Make a Change For LifeLearn more

    Wellmont LiveWell is creating a new tradition of wellness in the mountains by providing individuals with tools and encouragement to live healthier lifestyles.

  • HeartSHAPE Spotlight

    At risk for a heart attack? Learn more

    Fight heart disease early and prevent heart attacks with HeartSHAPE® - a painless, non-invasive test that takes pictures of your heart to scan for early-stage coronary disease.

  • Kidney Transplant Rejection Drugs Tied to Pregnancy Risks in Study

    Early research found more miscarriages, birth defects among women who conceived while on these meds
    WEDNESDAY, Oct. 23 (HealthDay News) -- Drugs meant to reduce the risk of organ rejection may increase the risk of miscarriage and birth defects when taken by female kidney transplant patients, according to a new study.
    The drugs -- called mycophenolic acid products -- reduce the risk of organ rejection by suppressing the immune system. The study included 163 female transplant patients who discontinued mycophenolic acid products prior to conception and 114 who conceived while taking the anti-rejection drugs.
    Those who stopped taking mycophenolic acid products before they became pregnant had more live births (79 percent vs. 43 percent), fewer miscarriages (19 percent vs. 52 percent) and a lower rate of birth defects (6 percent vs. 14 percent) than those who were taking the drugs when they conceived.
    Women who stopped the anti-rejection drugs before they became pregnant did not have an increased risk of kidney problems, according to the study, which is scheduled for presentation in early November at an American Society of Nephrology meeting in Atlanta.
    Although the study found an association between the drugs and increased pregnancy and birth risks, it did not prove a cause-and-effect relationship. The data and conclusions also should be viewed as preliminary until published in a peer-reviewed journal.
    "The results of this study generate multiple questions. Continued close collaboration among specialists will help to better identify potential pregnancy risks in kidney transplant recipients, particularly as new immunosuppressive [drugs] are developed," study author Dr. Serban Constantinescu, of the Temple University School of Medicine, said in an American Society of Nephrology news release.
    "Individual physicians and transplant centers are encouraged to report all pregnancy exposures in transplant recipients to the National Transplantation Pregnancy Registry, which was designed specifically to assess the safety of pregnancy in solid organ transplant recipients," Constantinescu said.
    More information
    The National Kidney Foundation has more about pregnancy and kidney disease (http://www.kidney.org/atoz/content/pregnancy.cfm ).
    SOURCE: American Society of Nephrology, news release, Oct. 23, 2013
  • Ideal Body Weight

    Ideal Body WeightLearn more

    Using body mass index as a reference, this calculator determines your ideal body weight range. All you need to do is enter your height.

  • Body Mass Index

    Body Mass IndexLearn more

    This tool considers your height and weight to assess your weight status.


  • Can we help answer your questions?

    Wellmont Nurse Connection is your resource for valuable health information any time, 24 hours a day, seven days a week. Speak to a Nurse any time, day or night, at (423) 723-6877 or toll-free at 1-877-230-NURSE.